DREAM Project Community Health Worker Intervention

October 16, 2017 updated by: NYU Langone Health
The DREAM (Diabetes Research, Education, and Action for Minorities) Project is a Community Health Worker (CHW) intervention to improve diabetic management and control among Bangladeshis with diabetes in New York City (NYC).

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

The DREAM (Diabetes Research, Education, and Action for Minorities) Project is a Community Health Worker (CHW) intervention to improve diabetic management and control among Bangladeshis with diabetes in New York City (NYC). For a two-arm, randomized controlled trial (RCT), investigators will recruit a sample of 256 participants, all of whom are 1) of Bangladeshi descent, 2) residing in NYC, 3) diagnosed with Type 2 diabetes mellitus (T2DM) and a recent Hemoglobin A1c (HbA1c) of ≥ 6.5, and 4) between the ages of 21-85. The treatment group receives a six-month CHW-led intervention consisting of five monthly group educational sessions, two one-on-one visits, and follow-up phone calls as needed from a CHW. The control group receives an introductory educational session only. Primary and secondary outcomes include clinical and behavioral measures, such as HbA1c and weight change, access to and utilization of care (i.e. appointment keeping and use of specialty care), and knowledge and practice of physical activity and healthful eating. Additionally, information regarding CHW characteristics, the processes and mechanisms for influencing healthful behavior change, and fidelity of the intervention are collected. Outcomes are measured at Baseline, 3-Months, 6-Months for both groups, and at 12-Months for the treatment group.

Study Type

Interventional

Enrollment (Actual)

441

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New York
      • New York, New York, United States, 10016
        • New York University School of Medicine, Dept of Population Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

25 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • confirmed clinical diagnosis of T2DM with a Hemoglobin A1c (HbA1c) of ≥ 6.5%; and
  • male or female between the ages of 21-85 years old; and
  • willingness to be randomized to either treatment or control groups.

Exclusion Criteria:

  • is or was on renal dialysis;
  • experiencing an acute or terminal illness or serious mental illness;
  • had a history of recent coronary event within the last 3 months of recruitment;
  • is pregnant at the time of recruitment;
  • experienced other severe medical conditions that might preclude participation;
  • has poor short-term prognosis (expected death in <2 years); or
  • is participating in another research study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Full CHW Intervention
5 monthly group educational sessions, 2 1v1 Visits with CHW, Phone Calls as Needed
5 group educational sessions, 2 1v1 Visits with a CHW, Phone Calls as needed during 6-month study period
No Intervention: Control: Intro to Diabetes Session Only
One-time, Introduction to Diabetes educational session only

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Baseline Hemoglobin A1c at 6-Months
Time Frame: Baseline, 6-Months
Change in Baseline HbA1c at 6-Months
Baseline, 6-Months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in Baseline Perceived Social Support at 6-Months
Time Frame: Baseline, 6-Months
Assessed using scale items on questionnaire instrument administered during semi-structured interview at each timepoint
Baseline, 6-Months
Change in Baseline Perceived Benefits & Barriers at 6-Months
Time Frame: Baseline, 6-Months
Assessed using scale items on questionnaire instrument administered during semi-structured interview at each timepoint
Baseline, 6-Months
Change in Baseline Self-Efficacy at 6-Months
Time Frame: Baseline, 6-Months
Assessed using scale items on questionnaire instrument administered during semi-structured interview at each timepoint
Baseline, 6-Months
Change in Baseline Access to / Utilization of healthcare at 6-Months
Time Frame: Baseline, 6-Months
Assessed using scale items on questionnaire instrument administered during semi-structured interview at each timepoint
Baseline, 6-Months
Change in Baseline Diabetic Management Practices & Knowledge at 6-Months
Time Frame: Baseline, 6-Months
Assessed using scale items on questionnaire instrument administered during semi-structured interview at each timepoint
Baseline, 6-Months
Change in Baseline Engagement in Physical Activity & Healthy eating at 6-Months
Time Frame: Baseline, 6-Months
Assessed using scale items on questionnaire instrument administered during semi-structured interview at each timepoint
Baseline, 6-Months
Change in Baseline Lipid Profile at 6-Months
Time Frame: Baseline, 6-Months
HDL, LDL, Triglycerides, Total Cholesterol
Baseline, 6-Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Nadia Islam, PhD, New York University School of Medicine, Department of Population Health

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 1, 2009

Primary Completion (Actual)

February 25, 2016

Study Completion (Actual)

February 25, 2016

Study Registration Dates

First Submitted

January 16, 2014

First Submitted That Met QC Criteria

January 21, 2014

First Posted (Estimate)

January 22, 2014

Study Record Updates

Last Update Posted (Actual)

October 18, 2017

Last Update Submitted That Met QC Criteria

October 16, 2017

Last Verified

October 1, 2017

More Information

Terms related to this study

Other Study ID Numbers

  • 09-0510
  • P60MD000538 (U.S. NIH Grant/Contract)
  • U48DP001904 (U.S. NIH Grant/Contract)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Diabetes Mellitus, Type 2

Clinical Trials on CHW Intervention

3
Subscribe